Compare Stocks → Crypto Market Preps For Trillions Worth of Inflows! (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:APVONASDAQ:BLPHNASDAQ:FCSCNASDAQ:INNTOTCMKTS:SEOVF Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$4.69+15.5%$6.08$3.81▼$92.62$2.02M4.93102,444 shs293,949 shsBLPHBellerophon Therapeutics$0.06$0.06$0.03▼$12.58$695K0.6732,450 shs60 shsFCSCFibrocell Science$3.00$3.00$1.45▼$3.28$29.28M1.6778,673 shsN/AINNTInnovate Biopharmaceuticals$0.97$0.37▼$1.67$8K-0.39525,982 shs253 shsSEOVFSernova$0.41+0.2%$0.44$0.37▼$0.83$124.76M1.1819,930 shs7,659 shs7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics+15.52%+4.69%-28.41%-41.11%-94.72%BLPHBellerophon Therapeutics0.00%+2.19%+8.63%+53.55%-99.26%FCSCFibrocell Science0.00%0.00%0.00%0.00%0.00%INNTInnovate Biopharmaceuticals0.00%0.00%0.00%0.00%-99.92%SEOVFSernova+0.19%+0.46%-9.29%-22.82%-34.85%This consistently signaled gains of 453%... 610%... and even 1036%... (Ad)It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPVOAptevo Therapeutics0.3183 of 5 stars0.02.00.00.03.00.01.3BLPHBellerophon Therapeutics1.8131 of 5 stars3.20.00.04.81.90.00.6FCSCFibrocell ScienceN/AN/AN/AN/AN/AN/AN/AN/AINNTInnovate BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASEOVFSernovaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPVOAptevo Therapeutics3.00BuyN/AN/ABLPHBellerophon Therapeutics2.33Hold$2.003,420.20% UpsideFCSCFibrocell ScienceN/AN/AN/AN/AINNTInnovate BiopharmaceuticalsN/AN/AN/AN/ASEOVFSernovaN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPVOAptevo Therapeutics$3.11M0.65N/AN/A$28.58 per share0.16BLPHBellerophon TherapeuticsN/AN/AN/AN/A$0.27 per shareN/AFCSCFibrocell Science$350K83.66N/AN/A$0.98 per share3.06INNTInnovate BiopharmaceuticalsN/AN/AN/AN/A($0.27) per shareN/ASEOVFSernovaN/AN/AN/AN/A$0.12 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPVOAptevo Therapeutics-$17.41MN/A0.00N/AN/AN/A-112.27%-64.39%5/9/2024 (Estimated)BLPHBellerophon Therapeutics-$19.83M-$0.84N/A∞N/AN/A-187.35%-104.97%3/29/2024 (Estimated)FCSCFibrocell Science-$10.28M-$1.45N/AN/AN/AN/A23.10%10.56%N/AINNTInnovate Biopharmaceuticals-$27.05MN/AN/AN/AN/AN/AN/A-234.42%N/ASEOVFSernova-$28.91M-$0.09N/A∞N/AN/A-146.71%-114.00%6/12/2024 (Estimated)Latest FCSC, APVO, BLPH, INNT, and SEOVF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/29/2024N/ABLPHBellerophon TherapeuticsN/A-$0.42-$0.42N/AN/AN/A3/18/2024Q1 2024SEOVFSernovaN/A-$0.02-$0.02-$0.02N/AN/A1/29/2024Q4 2023SEOVFSernovaN/A-$0.03-$0.03-$0.03N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPVOAptevo TherapeuticsN/AN/AN/AN/AN/ABLPHBellerophon TherapeuticsN/AN/AN/AN/AN/AFCSCFibrocell ScienceN/AN/AN/AN/AN/AINNTInnovate BiopharmaceuticalsN/AN/AN/AN/AN/ASEOVFSernovaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPVOAptevo TherapeuticsN/A2.642.64BLPHBellerophon TherapeuticsN/A3.963.96FCSCFibrocell Science0.475.095.09INNTInnovate BiopharmaceuticalsN/A0.350.35SEOVFSernovaN/A3.233.23OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPVOAptevo Therapeutics8.06%BLPHBellerophon Therapeutics10.61%FCSCFibrocell Science36.72%INNTInnovate Biopharmaceuticals5.88%SEOVFSernovaN/AInsider OwnershipCompanyInsider OwnershipAPVOAptevo Therapeutics1.90%BLPHBellerophon Therapeutics5.20%FCSCFibrocell Science1.10%INNTInnovate Biopharmaceuticals7.90%SEOVFSernovaN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPVOAptevo Therapeutics40430,000420,000Not OptionableBLPHBellerophon Therapeutics1812.23 million11.60 millionOptionableFCSCFibrocell Science199.76 millionN/AOptionableINNTInnovate Biopharmaceuticals841.33 millionN/ANot OptionableSEOVFSernovaN/A303.41 millionN/ANot OptionableFCSC, APVO, BLPH, INNT, and SEOVF HeadlinesSourceHeadlineSernova Names Nicholas Rossettos Interim CFOmarketwatch.com - March 11 at 1:39 PMSernova reports anticipated 2024 milestonesmsn.com - January 29 at 10:40 AMSernova gets FDA orphan drug, rare pediatric designations for hemophilia Amsn.com - November 27 at 8:15 PMClosing Bell: Sernova Corp flat on Tuesday (SVA)theglobeandmail.com - November 14 at 9:04 PMSernova Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System™ at the 2023 IPITA-IXA-CTRMS Joint Congressfinance.yahoo.com - October 30 at 7:35 AMSernova Presents Compelling New Data on the Cell Pouch System™ as a Promising Treatment for Post-Operative Hypothyroidism at the 2023 American Thyroid Association Annual Meetingfinance.yahoo.com - September 29 at 1:00 PMSernova Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Devicefinance.yahoo.com - September 7 at 10:11 AMSernova Appoints Cynthia Pussinen as Chief Executivemarketwatch.com - September 5 at 4:32 PMSernova appoints CEOseekingalpha.com - September 5 at 4:32 PMSernova reports positive interim data for Cell Pouch Systemmassdevice.com - June 26 at 6:49 PMSernova (SVA) Receives a Buy from H.C. Wainwrightmarkets.businessinsider.com - June 26 at 8:00 AMSernova to Present Updated Interim Phase 1/2 Clinical Data on Cell Pouch System™ During Oral Presentation at American Diabetes Association 83rd Scientific Sessionsfinance.yahoo.com - June 22 at 6:01 PMSernova is significantly undervalued, says Echeloncantechletter.com - June 16 at 11:36 PMSernova to Participate in Upcoming Truist Securities Cell Therapy Symposiumfinance.yahoo.com - June 16 at 1:35 PMEchelon Wealth Partners Remains a Buy on Sernova (SVA)markets.businessinsider.com - June 15 at 3:50 PMSernova Announces Executive Alignment and Appoints New Board Chairfinance.yahoo.com - May 31 at 8:58 AMClosing Bell: Sernova Corp flat on Monday (SVA)theglobeandmail.com - May 8 at 9:43 PMSernova Corp. Announces Voting Results of the 2023 Annual General Meeting of Shareholdersthenewswire.com - April 28 at 3:38 PMClosing Bell: Sernova Corp flat on Thursday (SVA)theglobeandmail.com - April 28 at 10:37 AMConcerned Shareholders of Sernova Corp. Wish to Thank All Shareholdersfinance.yahoo.com - April 25 at 6:02 PMSernova Reminds Shareholders to Vote FOR the Eight Management Director Nominees Using ONLY the WHITE Management Proxythenewswire.com - April 21 at 12:40 PMProxy adviser backs diabetes device developer Sernova in fight against activist investorsmedtechdive.com - April 17 at 3:33 PMSernova to Present at 2023 Alliance for Regenerative Medicine Cell & Gene Meeting on the Medfinance.yahoo.com - April 10 at 8:20 AMSernova defends record after investors attack ‘sluggish’ progress of regenerative medicine implantmedtechdive.com - April 7 at 3:12 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAptevo TherapeuticsNASDAQ:APVOAptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and. ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers. Its preclinical candidates include APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; APVO711, a dual mechanism bispecific ADAPTIR candidate designed to provide synergistic stimulation of CD40 on antigen presenting cells; and APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Bellerophon TherapeuticsNASDAQ:BLPHBellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.Fibrocell ScienceNASDAQ:FCSCFibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania.Innovate BiopharmaceuticalsNASDAQ:INNTInnovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.SernovaOTCMKTS:SEOVFSernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.